Category: GLP-1/GIP/Glucagon Triple Agonist Research Peptide

Reta 20mg is a high-strength research vial of Retatrutide, the groundbreaking triple receptor agonist that simultaneously activates GLP-1, GIP, and Glucagon receptors. This multi-pathway mechanism makes Retatrutide one of the most advanced investigational peptides for studies in obesity, type 2 diabetes, fatty liver disease, and metabolic health.

At 20mg per vial, Reta provides double the research material compared to standard 10mg vials, making it ideal for extended studies or higher-dose research protocols. By enhancing satiety, reducing caloric intake, increasing fat metabolism, and improving insulin sensitivity, Reta 20mg has emerged as a leading next-generation compound for metabolic exploration.

Key Features:

• 20mg high-potency research vial

• First-in-class triple receptor agonist (GLP-1, GIP, Glucagon)

• Investigational focus: weight management, glycaemic control, and metabolic disease reversal

• Longer half-life designed for convenient weekly administration in research models

• Stronger potency for extended or higher-volume studies

CAS Number: 2381089-83-2

Disclaimer:
Reta 20mg is provided strictly for research purposes only. Not for human consumption, medical, or veterinary use.